Exosomes have incredible properties that enable researchers to engineer exosomes as carriers for the delivery of drugs, as well as perfectly target tissues of interest, while evading or modulating immune responses. Today, drug delivery and development of exosome-mediated therapies is a growing market segment, with over 60 companies forging ahead in this field. Many of the recent advances in exosome research are technology-based and this helps researchers to quantify exosome cargoes and subtypes, allowing for the tracking of exosomes with remarkable precision. This is helping companies to regulate exosome drug dosage and delivery, as well as delivering effective treatments for hard-to-treat diseases, such as cancer and neurodegenerative diseases. [Read more…]
Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes)
July 24, 2025, St. Louis, Missouri — Future Medical Products LLC is pleased to announce the launch of PBME Topical (“Pure Bone Marrow Exosomes”). PBME Topical is a cosmetic product in compliance with the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
PBME Topical consists of isolated exosomes from mesenchymal stem cells, the most studied cell in science. These exosomes are composed of phospholipid bilayers with transmembrane proteins and receptors, integrated growth factors, in addition to micro-RNA and messenger-RNA. Exosomes are naturally found in every part of the body, but the source of the exosomes intended for aesthetics, as well as regenerative medicine, is critical. Bone marrow exosomes are considered by some to be the purest form of stem cell therapy without the cell. [Read more…]
Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes
-
‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only recombinant, stable and functional form of Adiponectin
-
First preclinical results confirm remarkable therapeutic potential in treatment of several metabolic diseases, in particular type 2 diabetes and obesity, affecting around two billion patients worldwide
-
Ciloa plans to use funding to implement biomanufacturing of candidate APN-sEV and demonstrate that innovative biotherapy meets all safety criteria to enter clinical phases I and IIa in treatment of obesity and type 2 diabetes
Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research
MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration. [Read more…]
Winner of the “Biotherapies and Bioproduction” Call for Projects Under the France 2030 plan, EVerZom Receives €3M in Government Funding to Industrialize its Exosome Bioproduction Technology
Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the “Biotherapies and Bioproduction of Innovative Therapies” call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 27
- Next Page »